![Robert L. Simon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Robert L. Simon
Former positions of Robert L. Simon
Companies | Position | Start | End |
---|---|---|---|
GILEAD SCIENCES, INC. | General Counsel | 2000-06-30 | 2001-11-30 |
BRISTOL-MYERS SQUIBB COMPANY | General Counsel | 1986-12-31 | 2000-06-30 |
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | General Counsel | 2012-03-31 | - |
OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2001-12-31 | - |
Training of Robert L. Simon
San Jose State University | Undergraduate Degree |
Statistics
International
United States | 6 |
Operational
General Counsel | 3 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private companies | 2 |
---|---|
OSI Pharmaceuticals, Inc.
![]() OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Threshold Pharmaceuticals, Inc.
![]() Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Stock Market
- Insiders
- Robert L. Simon
- Experience